Regorafenib治疗肝癌的临床研究进展
Regorafenib, a novel multi-kinase inhibitor, has been approved for the treatment of metastatic colorectal cancer and gastrointestinal stromal tumors. The clinical trials of Regorafenib for the treatment of hepatocellular carcinoma (HCC) are summarized. Phase Ⅰ and Ⅱ clinical trials have demonstrated...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Editorial Department of Journal of Clinical Hepatology
2014-03-01
|
| Series: | Linchuang Gandanbing Zazhi |
| Subjects: | |
| Online Access: | http://www.lcgdbzz.org/qk_content.asp?id=5738&ClassID=331688 |